A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
← catalyst calendarNCT05514054 · readout ≤ 437 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
8,000estimated
Sites
672
Countries
Argentina, Australia, Austria +28
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-04 | actual | When the study began enrolling |
| Primary completion | Oct 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Neoplasms
Interventions
- Drug: Imlunestrant — also filed as LY3484356
- Drug: Tamoxifen
- Drug: Anastrozole
- Drug: Letrozole
- Drug: Exemestane
Primary outcome
what the primary-completion date above is the date OFInvasive Disease-Free Survival (IDFS)
measured Randomization to recurrence or death from any cause (up to 10 years)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed